307 related articles for article (PubMed ID: 18854695)
41. Management of thyroid eye disease.
Bartalena L; Marcocci C; Tanda L; Pinchera A
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S458-65. PubMed ID: 12192546
[TBL] [Abstract][Full Text] [Related]
42. Understanding the clinical and molecular basis of thyroid orbitopathy: a review of recent evidence.
Nivean PD; Madhivanan N; Kumaramanikavel G; Berendschot TTJM; Webers CAB; Paridaens D
Hormones (Athens); 2024 Mar; 23(1):25-34. PubMed ID: 37910311
[TBL] [Abstract][Full Text] [Related]
43. The pathophysiology of thyroid eye disease: implications for immunotherapy.
Douglas RS; Gupta S
Curr Opin Ophthalmol; 2011 Sep; 22(5):385-90. PubMed ID: 21730841
[TBL] [Abstract][Full Text] [Related]
44. The Role of Biological Agents and Immunomodulators in Treatment Strategies for Thyroid Eye Disease: An Evidence-based Review.
Ginter A; Migliori ME
R I Med J (2013); 2016 Jun; 99(6):26-9. PubMed ID: 27247969
[TBL] [Abstract][Full Text] [Related]
45. Optimal management of Graves orbitopathy: a multidisciplinary approach.
Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
[TBL] [Abstract][Full Text] [Related]
46. Analysis of Periorbital Soft Tissue in Thyroid Eye Disease.
Mimura M; Yang PT; Ko AC; Korn BS; Kikkawa DO
Ophthalmic Plast Reconstr Surg; 2020; 36(1):30-33. PubMed ID: 31567914
[TBL] [Abstract][Full Text] [Related]
47. The changing landscape of thyroid eye disease: current clinical advances and future outlook.
Moledina M; Damato EM; Lee V
Eye (Lond); 2024 Jun; 38(8):1425-1437. PubMed ID: 38374366
[TBL] [Abstract][Full Text] [Related]
48. Serum Vitamin D Deficiency Is an Independent Risk Factor for Thyroid Eye Disease.
Heisel CJ; Riddering AL; Andrews CA; Kahana A
Ophthalmic Plast Reconstr Surg; 2020; 36(1):17-20. PubMed ID: 31568022
[TBL] [Abstract][Full Text] [Related]
49. Evaluation and management of Graves' orbitopathy.
Lee HB; Rodgers IR; Woog JJ
Otolaryngol Clin North Am; 2006 Oct; 39(5):923-42, vi. PubMed ID: 16982255
[TBL] [Abstract][Full Text] [Related]
50. Graves orbitopathy: update on diagnosis and therapy.
Melcescu E; Horton WB; Kim D; Vijayakumar V; Corbett JJ; Crowder KW; Pitman KT; Uwaifo GI; Koch CA
South Med J; 2014 Jan; 107(1):34-43. PubMed ID: 24389785
[TBL] [Abstract][Full Text] [Related]
51. A 'Real Life' Service Evaluation Model for Multidisciplinary Thyroid Eye Services.
Farag S; Feeney C; Lee V; Nagendran S; Jain R; Aziz A; Akishar R; Bravis V; Meeran K
Front Endocrinol (Lausanne); 2021; 12():669871. PubMed ID: 34025584
[TBL] [Abstract][Full Text] [Related]
52. Pathophysiology of intraocular pressure increase and glaucoma prevalence in thyroid eye disease: a mini-review.
Haefliger IO; von Arx G; Pimentel AR
Klin Monbl Augenheilkd; 2010 Apr; 227(4):292-3. PubMed ID: 20408077
[TBL] [Abstract][Full Text] [Related]
53. Minimally invasive surgery for thyroid eye disease.
Naik MN; Nair AG; Gupta A; Kamal S
Indian J Ophthalmol; 2015 Nov; 63(11):847-53. PubMed ID: 26669337
[TBL] [Abstract][Full Text] [Related]
54. Thyroid Eye Disease and Its Association With Diabetes Mellitus: A Major Review.
Gupta R; Kalra P; Ramamurthy LB; Rath S
Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S51-S64. PubMed ID: 38054986
[TBL] [Abstract][Full Text] [Related]
55. The role of intravenous methylprednisolone immunosuppression in the management of active thyroid eye disease.
Tambe K; Bhargava J; Tripathi A; Gregory M; Burns J; Sampath R
Orbit; 2010 Oct; 29(5):227-31. PubMed ID: 20812826
[TBL] [Abstract][Full Text] [Related]
56. Clinical update: treatment of hyperthyroidism in Graves' ophthalmopathy.
Azzam I; Tordjman K
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():193-7. PubMed ID: 20467362
[TBL] [Abstract][Full Text] [Related]
57. Tumors masquerading in patients with thyroid eye disease.
Griepentrog GJ; Burkat CN; Kikkawa DO; Lucarelli MJ
Orbit; 2013 Aug; 32(4):260-2. PubMed ID: 23662589
[TBL] [Abstract][Full Text] [Related]
58. In vivo ocular biomechanical compliance in thyroid eye disease.
Vellara HR; Hart R; Gokul A; McGhee CNJ; Patel DV
Br J Ophthalmol; 2017 Aug; 101(8):1076-1079. PubMed ID: 27941044
[TBL] [Abstract][Full Text] [Related]
59. Identification of immune-related regulatory networks and diagnostic biomarkers in thyroid eye disease.
Tong X; Shen Q
Int Ophthalmol; 2024 Feb; 44(1):38. PubMed ID: 38332455
[TBL] [Abstract][Full Text] [Related]
60. Thyroid-associated ophthalmopathy in Iranian patients.
Kashkouli MB; Jam S; Sabzvari D; Ketabi N; Azarinia S; SeyedAlinaghi S; Mofid A
Acta Med Iran; 2011; 49(9):612-8. PubMed ID: 22052145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
